Humacyte(US:HUMA) Prnewswire·2024-12-19 10:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Humacyte, Inc. regarding a class action lawsuit due to alleged misleading statements and failures to disclose critical information during a specified class period [1][2]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from May 10, 2024, to October 17, 2024 [2]. - Allegations include that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, which included issues with quality assurance and microbial testing [2]. - It is claimed that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies, posing a substantial risk to FDA approval of their acellular tissue engineered vessel for vascular trauma [2]. - The lawsuit asserts that the positive statements made by the company regarding its business and prospects were materially misleading and lacked a reasonable basis [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of January 17, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [4].